WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205879
Description: Laniquidar is a third-generation P-gp inhibitor, which has been used in clinic trials for modulating multidrug resistance transporters. A study of docetaxel in combination with the new orally administered P-glycoprotein (P-gp) inhibitor R101933 showed that this combination was feasible. However, due to the low oral bioavailability of R101933 and high interpatient variability, no further attempts to increase the level of P-gp inhibition were made.
MedKoo Cat#: 205879
Chemical Formula: C37H36N4O3
Exact Mass: 584.27874
Molecular Weight: 584.70674
Elemental Analysis: C, 76.00; H, 6.21; N, 9.58; O, 8.21
Laniquidar is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Synonym: Laniquidar; R101933; R 101933; R-101933.
IUPAC/Chemical Name: methyl 11-(1-(4-(quinolin-2-ylmethoxy)phenethyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepine-3-carboxylate
InChi Key: TULGGJGJQXESOO-UHFFFAOYSA-N
InChi Code: InChI=1S/C37H36N4O3/c1-43-37(42)34-24-38-36-35(32-8-4-2-6-27(32)19-23-41(34)36)29-17-21-40(22-18-29)20-16-26-10-14-31(15-11-26)44-25-30-13-12-28-7-3-5-9-33(28)39-30/h2-15,24H,16-23,25H2,1H3
SMILES Code: O=C(C1=CN=C2N1CCC3=CC=CC=C3/C2=C4CCN(CCC5=CC=C(OCC6=NC7=CC=CC=C7C=C6)C=C5)CC\4)OC
The following data is based on the product molecular weight 584.70674 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Moerman L, Dumolyn C, Boon P, De Vos F. The influence of mass of [11C]-laniquidar and [11C]-N-desmethyl-loperamide on P-glycoprotein blockage at the blood-brain barrier. Nucl Med Biol. 2012 Jan;39(1):121-5. Epub 2011 Sep 29. PubMed PMID: 21958857.